Pacira BioSciences (PCRX) Revenue (2010 - 2026)

Pacira BioSciences' Revenue history runs 17 years deep, the most recent figure standing at $177.4 million for Q1 2026.

• On a quarterly basis, Revenue rose 5.0% year-over-year to $177.4 million in Q1 2026; TTM through Mar 2026 was $734.9 million, a 4.57% increase from a year earlier, with the FY2025 full-year figure at $726.4 million, up 3.63% from the prior year.
• Revenue slipped to $177.4 million in Q1 2026 per PCRX's latest filing, from $196.9 million in the prior quarter.
• Across five years, Revenue topped out at $196.9 million in Q4 2025 and bottomed at -$492.2 million in Q4 2022.
• The 5-year median for Revenue is $169.4 million (2022), against an average of $134.3 million.
• Across the five-year window, Revenue slumped 409.18% in 2022 and surged 136.82% in 2023, its largest moves.
• Year by year, Revenue stood at -$492.2 million in 2022, then surged by 136.82% to $181.2 million in 2023, then rose by 3.32% to $187.3 million in 2024, then rose by 5.14% to $196.9 million in 2025, then declined by 9.9% to $177.4 million in 2026.
• Per Business Quant, the three latest PCRX Revenue figures stand at $177.4 million (Q1 2026), $196.9 million (Q4 2025), and $179.5 million (Q3 2025).